Cord Blood News Volume 7.48 | Dec 10 2015

    0
    108

    Cord Blood News 7.48 December 10, 2015

    Cord Blood News

         In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  CBN on Twitter

     
    TOP STORY
    Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft
    Researchers evaluated the feasibility and safety of StemRegenin-1 (SR-1), an aryl hydrocarbon receptor antagonist that expands CD34+ cells, by placing one of the two units in expansion culture. SR-1 produced a 330-fold increase in CD34+ cells and led to engraftment in 17/17 patients at a median of 15 days for neutrophils and 49 days for platelets, significantly faster than in patients treated with unmanipulated umbilical cord blood. [Cell Stem Cell] Abstract | Graphical Abstract
    Only One of These Antibodies Will Work for Your Cell Analysis. We Provide Streamlined Solutions that are Reliable and Save You Time

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    Umbilical Cord Mesenchymal Stromal Cell with Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion
    Scientists determined the safety and effects on insulin secretion of umbilical cord mesenchymal stromal cells plus autologous bone marrow mononuclear cell stem cell transplantation without immunotherapy in established type 1 diabetes. [Diabetes Care] Abstract

    Investigating the Potential of Human Placental Derived Extracellular Matrix Sponges Coupled with Amniotic Membrane-Derived Stem Cells for Osteochondral Tissue Engineering
    Scientists fabricated human placental derived extracellular matrix sponges (PEMS) for repair of osteochondral tissue through a decellularization process. In vitro, PEMS provided a non-cytotoxic and bioactive cues rich environment for the human amniotic membrane derived stem cells to proliferate and differentiate into chondrogenic and osteogenic lineage under induction. [J Mater Chem B] Abstract

    Placenta Mesenchymal Stem Cell Derived Exosomes Confer Plasticity on Fibroblasts
    The authors isolated human placenta mesenchymal stem cell-derived exosomes and examined their function in vitro. [J Cell Biochem] Abstract

    Mast Cells Release Chemokine CCL2 in Response to Parkinsonian Toxin 1-Methyl-4-Phenyl-Pyridinium (MPP+)
    Investigators analyzed if MPP+ activates mouse and human mast cells to release chemokine (C-C motif) ligand 2 (CCL2). Mouse bone marrow-derived mast cells and human umbilical cord blood-derived cultured mast cells were incubated with MPP+ for 24 hours and CCL2 levels were measured in the supernatant media by ELISA. [Neurochem Res] Abstract

    Inverse Association between Maternal 25OHD Level and Cord GLP-1/GIP Concentrations
    Scientists explored whether maternal 25-hydroxyvitamin D levels in normal pregnancy have association with diabetes-related hormone levels and glycated albumin. A prospective cohort study was performed to collect serum samples from 612 pairs of pregnant women and cord blood of their offspring. [Pediatr Res] Abstract

    Isolation and Morphological Characterization of Ovine Amniotic Fluid Mesenchymal Stem Cells
    Researchers obtained mesenchymal stem cells from ovine amniotic fluid and determined the expansion capacity, surface and intracellular marker expression, karyotype, and multilineage differentiation ability of these ovine amniotic fluid mesenchymal stem cells. [Exp Anim] Abstract

    SmartDishâ„¢ with STEMgridâ„¢-6 for Accurate Counting of Hematopoietic CFU Assays

     
    REVIEWS
    Methods of Ex Vivo Expansion of Human Cord Blood Cells: Challenges, Successes and Clinical Implications
    The authors review the current landscape of cord blood engineering aimed at improving engraftment. This includes approaches of unrelated cord blood-hematopoietic stem and progenitor cells (UCB-HSPCS) expansion and methods aimed at improving UCB-HSCPs homing. [Expert Rev Hematol] Abstract

    Visit our reviews page to see a complete list of reviews in the cord blood research field.

     
    SCIENCE NEWS
    Multiple Myeloma Patient Study Shows Promise for Natural Killer Cells
    A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient’s own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments. [Press release from MD Anderson Cancer Center discussing research presented at the 57th American Society of Hematology (ASH) Annual Meeting, Orlando] Press Release

    From our sponsor:
    Learn about mucociliary differentiation of primary bronchial epithelial cells.
    Watch the video.

     
    INDUSTRY NEWS
    Gamida Cell Reports Positive Top Line Results of International, Multi-Center, Phase I/II Study of NiCord® for Blood Cancers, Demonstrating Rapid and Durable Hematopoietic Recovery
    Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, announced positive top line results from the Phase I/II study of NiCord, in development as an experimental treatment for patients with blood cancers. [Gamida Cell (Business Wire)] Press Release

    Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKAâ„¢ (Bendamustine Hydrochloride) Injection
    Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved BENDEKAâ„¢ injection. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. [Teva Pharmaceutical Industries Ltd.] Press Release

    NYBC Scientists Awarded Patents for Discoveries to Protect Our Blood Supply and Advance Vaccine Therapies
    New York Blood Center announced the award of several new patents, continuing its unique role as an independent, community-based blood center that also operates a successful research institute dedicated to developing products and services that benefit patients worldwide. [New York Blood Center (PR Newswire Association LLC.)] Press Release

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW The Controlling Cancer Summit 2016
    May 17-19, 2016
    London, United Kingdom

    Visit our events page to see a complete list of events in the cord blood community.

     
    JOB OPPORTUNITIES
    NEW Full Member Faculty – Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center)

    Postdoctoral Research Scientist – Lymphocyte Trafficking Mechanisms in Allogeneic Stem-Cell Transplantation (Columbia University Medical Center)

    Associate/Full Professor – Stem Cell Biology and Regeneration Medicine (Guangzhou Women and Children’s Medical Center)

    Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

    Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

    Faculty Positions – Regenerative Medicine for Organ Regeneration or Transplantation (The University of Texas Medical School at Houston)

    Postdoctoral Fellow – Leukemia Research (City of Hope)

    Faculty Member – Hematopoietic Cell Transplant (Fred Hutchinson Cancer Research Center)

    Assistant or Associate Professor – Cell and Regenerative Biology (University of Wisconsin, Madison)

    Assistant Member – Cord Blood Transplantation (Fred Hutchinson Cancer Research Center)

    Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)


    Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Cord Blood News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Cord Blood News: Archives | Events | Contact Us